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Introduction
Hepatic dysfunction is a common co-morbid condition of
coronary artery disease (CAD). Although the precise cause
and effect is still dubious, the crucial role of liver in
regulating lipids and carbohydrate metabolism is not
debatable. CAD patients experience insulin resistance (IR)
and dyslipidaemia, with subsequent oxidative stress and
chronic systemic inflammation. All these factors have
independent deleterious effects on hepatocytes. The
medications used for treating CAD or other co-morbidities
further exacerbate the hepatic damage. Statins, for
example, have well-recognised adverse effects on liver
function.1
When the liver is under stress as in chronic CAD, the
hepatocytes disintegrate, releasing aspartate
aminotransferase (AST), alanine aminotransferase (ALT) and
gamma-glutamyl transferase (GGT) into the blood.
Interestingly, the implication of elevated serum level of
these three biomarkers is not just limited to hepatic
dysfunction, as they also imply cardio-metabolic
abnormalities with sufficient evidence indicating that these
hepatic biomarkers are also associated with cardiovascular
disease (CVD) risk. Analysis of the British Women’s Heart
and Health Study and Meta-analysis involving around 3,000
women concluded that even minor increase in serum GGT
by just 1U/L can increase the risk of CVD by 20%, and risk
of CAD and stroke by 34%.2 Another study involving more
than 1,800 healthy men from the general population
indicated GGT as a robust predictor of an acute coronary
event independent of other CVD risk factors.3 Moderately
high GGT, still within normal range, is reported to increase
the risk of an incident of CAD, and is an independent
prognostic marker of re-infarction and cardiac death in
CAD patients.4
Similar is the case for elevated aminotransferases, which
are positively associated with severity of atherosclerosis
and IR.5 Results from the National Health and Nutrition
Examination Survey showed that slight elevation of serum
ALT concentrations, still within optimum range, is linked to
higher CAD risk, and associated histological changes of
fatty liver.6 In contrast, AST is associated more with diabetic
complications involving IR7 and impaired glucose tolerance
(IGT).8
Higher concentration of AST, ALT and GGT in the serum of
CAD patients could indicate a concurrent or prospective
non-alcoholic fatty liver disease, with dire health
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consequences. We need safer and inexpensive alternates,
like nuts, which are good for cardio-metabolic health.9
Almonds have shown to improve lipid profile,10 glycaemic
control,11 and oxidative stress.12 None of the animal studies
looking at the hepatic effects of almonds have used whole
or soaked almonds. Instead, they have used almond oils13,14
and skin extracts.15 To the best of our knowledge, there is
no clinical study on hepato-protective effect of almonds
except one16 which has looked at AST and ALT in the
context of weight reduction, but it used a very high dose
of almonds 50 gm/daily and a hypo-caloric background
diet, while limit itself to female subjects with high body-
weights. Knowing that the cost of treatment is an
important consideration when situation demands life-long
use in chronic disorders, it was recently shown that a dose
of almonds as low as 10g/day is effective in improving lipid
profile and uric acid in CAD patients when used according
to South-Asian tradition, taking them on empty stomach
and after overnight soaking.17,18 According to the Food and
Agriculture Organisation of the United Nations, Pakistan
ranks 17th on the list of almond-producing countries in the
world.19 Portugal ranks 19th and it has evaluated the
biological properties of locally-grown almonds. India is not
in the list of top 20 almond-growers,19 and yet it has
studied the nutritional properties of its almonds. To the
best of our knowledge, there is no study exploring the
medicinal properties of Pakistani almonds. The current
study was planned to compare the effect of Pakistani and
American almonds on serum concentration of liver
enzymes in CAD patients. 
Subjects and Methods
The randomised controlled trial (RCT) was conducted at the
Cardiology Clinics of Aga Khan University Hospital, Karachi,
from February to July, 2012. Approval was obtained from
the institutional Clinical Trial Unit (CTU) and Ethical Review
Committee (ERC), and the RCT was registered at the
Australian New Zealand Clinical Trial Registry20 (Trial
number: ACTRN12614000036617; URL: http://www.anzctr.
org.au). The study is an offshoot of an original research
designed to inspect changes in serum high-density
lipoprotein (HDL) levels as the primary outcome. The study
design with eligibility criteria, participants’ flow and sample
size calculation, as well as the findings have already been
published.17,18
Those included were patients of CAD, as diagnosed by their
respective cardiologists. After obtaining consent, baseline
blood samples were collected, questionnaires were
administered, and the participants were randomised into
three groups using computer-generated block
randomisation which was done using sealed envelopes
provided by CTU. Group 1 was given no intervention (NI),
Group 2 was given Pakistani almonds (PA) and Group-3 was
given American almonds (AA). 
Blood samples were taken at baseline and follow-up visits
at week 6 and 12. Each time, vitals were recorded, and
physical activity and food frequency questionnaires were
administered. Pre-packed almonds 10g/d were provided to
PA and AA groups. As per traditional recommendation, the
participants were requested to soak the almonds
overnight, remove the skin in the morning, and eat before
breakfast. Compliance was monitored by patient diaries
and reminder phone calls.
Serum concentrations of AST, ALT and GGT were estimated
on an automated analyser (Roche Cobas c-111, PK) using
commercially available kits. For comparing means, two-way
analysis of variance (ANOVA) with repeated measure was
used, followed by Bonferroni post-test. Results were
expressed as meansstandard error of mean (SEM), and p<
0.05 was considered significant.
Results
Of the 150 subjects, 113 were males and 37 were females.
The overall age range was 32-86 years, and mean body
weight was 7612kg. Of the total, 110 (73.3%) completed
the study, and of them, 38 (34.5%) were in PA group, 
41 (37.3%) in AA, and 31 (28.2%) in the NI group.  Food
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Figure-1: Impact of three-month almond supplementation on aspartate 
aminotransferase (AST) levels in male (A) and female 
(B) coronary artery disease (CAD) patients.
All values are expressed as mean±standard error of mean (SEM); *p-value < 0.05, ** p-value < 0.01
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consumption, physical activity patterns, and drug regimens
remained unchanged across the groups during the study
(p>0.05). PA and AA subjects showed  significant
improvement in serum concentrations of AST, ALT and GGT
at 12 weeks compared to NI controls (p<0.05), as well as
compared to their own respective baseline values (p<0.05).
At 6 weeks, the values were not significant (p>0.05) Dietary
supplementation of both Pakistani and American almonds
produced similar effects (p>0.05). 
Mean serum AST concentration in PA and AA groups
decreased from 27.651 and 26.751.1 U/L at baseline to
25.451.1 and 25.31 U/L (p>0.05) at 6 weeks, and 23.21.1
and 21.851U/L (p<0.05) at 12 weeks. In the NI group, the
concentrations were 27.20.9U/L at baseline, 28.21.1 at
week 6 and 26.9+1U/L at week 12 (p>0.05) (Figure 1). ALT
concentration in NI was 37.71.2U/L at baseline, 37.31.1
at week 6 and 36.91U/L at week 12 (p>0.05. ALT
concentration dropped from 39.651.33 to 36+0.8 and
then to 35.350.95 U/L (p< 0.05) in PA group, and from
38.31.1 to 35.20.7 and then to 33.90.8 U/L (p<0.05) in
AA group (Figure 2). 
Serum GGT concentrations at baseline were 20.351.2,
21.550.8 and 22.41.0U/L in NI, PA and AA groups,
respectively. At week 6, the concentrations changed to
19.451.1 and 21.31 U/L in PA and AA respectively
(p>0.05). The change in NI group was not significant
(p>0.05). At week 12, GGT concentrations in the NI group
remained unchanged at 20.31.6U/L (p>0.05), while in PA
and AA groups it decreased to 17.251 and 17.60.9U/L
(p<0.05) (Figure 3). 
There was no significant change in systolic or diastolic
blood pressure, heart rate or body-weights of the
participants in any of the three groups (p>0.05).
Discussion
The findings showed a reduction in the concentration of
AST, ALT and GGT in the serum of CAD patients, indicating
the potential of almonds to protect the liver from damage
and dysfunction. To the best of our knowledge, this is the
first clinical trial on almonds, showing protection of CAD-
associated hepatic complications at a very low dose when
taken on empty stomach after overnight soaking. This is
also the first attempt to scientifically evaluate Pakistani
almond variety and show that the bio-efficacy of this
cultivar is similar to American almonds. We need full-scale
clinical trials and molecular research to find out exactly how
whole almonds may prevent, and possibly treat, human
hepatic dysfunction, but these preliminary results are
significant on their own.
Hepatic effects of other components of almonds, like
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Figure-2: Impact of three-month almond supplementation on alanine 
aminotransferase (ALT) levels in male (A) and female 
(B) coronary artery disease (CAD) patients.
All values are expressed as mean±standard error of mean (SEM); *p-value < 0.05, ** p-value < 0.01 
Figure-3: Impact of three-month almond supplementation on gamma-glutamyl
transferase (GGT) levels in male (A) and female (B) coronary artery
disease (CAD) patients.
All values are expressed as mean±standard error of mean (SEM); *p-value < 0.05, ** p-value < 0.01 
oils13,14 or skin extracts,15 have also been tested in animal
models. An earlier study15 found that certain extracts of
almond skin can protect hepatocytes from oxidative stress.
They elaborated the anti-oxidative potential using cell and
tissue preparations and particularised microsomal lipid
peroxidation and cell death.15 One study13 assessed the
hepatic effects of almond oil in a rat model of acute liver
damage, and found reduction in AST and ALT, with a
concurrent lowering of cholesterol, triglycerides, and
lipoproteins in the serum. They also reported an anti-
oxidative effect in superoxide dismutase (SOD), glutathione
peroxidase (GSH) and malondialdehyde (MDA) assays.13 A
similar reduction in hepatic biomarkers, oxidative stress
and lipid profile by almond oil was reported by a study14
which used carbon tetrachloride (CCL4)-induced hepatic
toxicity in rats. It found that a formulation containing
almonds, flaxseeds and olive oil significantly reduced
serum AST, ALT, cholesterol, triglycerides, MDA and SOD. In
contrast, a study21 used extracts of bitter almonds in the rat
model of streptozotocin-induced diabetes. The extracts
positively affected some of the liver fatty acids, inhibited
post-prandial glycaemia and showed an antioxidant effect
in the MDA and GSH assays.22
It has previously been shown in a rat model that dietary
almond supplementation prevented high-fat diet-induced
hepatic damage and potentially inhibited cholesterol
synthesis via HMG-CoA reductase inactivation.23 It was
further observed that high-fat diet led to prominent fatty
lesions on rat livers,24 which were absent in the almond-
treated rats (unpublished data). This encouraged us to
explore whether dietary almonds can prevent fatty liver or
associated complications in chronic diseases.
The only human study using almond intervention and liver
enzymes16 used a large dose of almond at 50 grams/day
added to low-calorie diets of obese and overweight
women. After three months, body-weights reduced with
significant improvement in liver enzymes.16 Conflictingly,
we did not find a change in body-weight, which may be
because of the hypocaloric versus habitual diets.
Interestingly, using an almond dose that was five times less
than that used earlier,16 the current study observed a
comparable reduction in liver enzymes. This means that
soaking almonds overnight and eating before breakfast
may have added benefits with better bioavailability.
Previously, in rodent models, it was found that a low dose
of almonds eaten on empty stomach is equally effective as
high dose taken with food.22,25,26 Digestion, absorption and
content bio-accessibility is maximised when there are no
hindering food particles.26
Raised hepatic biomarkers AST, ALT and GGT in the serum
are not just interpreted as indicating hepatic
destruction/dysfunction, but their implication in CVD
prognosis is now being recognised by the scientific
community, and research is directed towards
understanding their role in the pathogenesis of
atherosclerotic vascular diseases. While the precise
mechanistic contributions of these biomarkers in CAD are
still uncertain, it is known that hepatic damage
compromises the physiological state and limits treatment
options for CAD patients.
GGT is not confined only to hepatocytes. It is found on
membranes of other cell types too where it is anticipated
to be involved in atherosclerotic progression.27 Active GGT
has been identified in plaques that block the coronary
arteries in CAD patients where it is shown to be producing
reactive oxygen species which damages deoxyribonucleic
acid (DNA), proteins, and circulating lipids.28 Oxidised lipids
in turn promote the formation of foam cell in the
atheromatous plaques.
AST is also not specific to the liver cells, as it it is present in
the heart, kidneys and blood cells among others. It may get
released if any of these organs experience cellular damage
due to oxidative stress or inflammation. ALT, however, is
highly restricted to the cytoplasm of liver cells and elevated
levels mostly indicate hepatocellular destruction.24
Conclusion
Almonds were found to potentially protect the liver of CAD
patients at distinctly low dose of 10 g/day when taken on
an empty stomach after overnight soaking. Knowing that
natural edible products are safer than medications and act
through multiple target sites, they can be promoted as
preventive remedy to avert hepatic dysfunction associated
with chronic diseases, like CVDs, and cost-effectiveness can
be assured when taken in a South Asian traditional way.
Disclaimer: The original trial with high-density lipoprotein
(HDL) as the primary outcome was part of a doctorate
thesis. The results presented here were not included in the
dissertation, as these analyses were conducted later.
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